INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by an increase and unregulated growth of predominantly myeloid cells in the bone marrow, and their accumulation in the blood (1) . A hallmark of CML is the Philadelphia chromosome, resulting from a reciprocal translocation between the long arms of chromosomes 9 and 22 (2, 3) . This chromosomal translocation leads to expression of BCR-ABL, an oncogenic fusion protein with a constitutively activated ABL tyrosine kinase. BCR-ABL can transform myeloid progenitor cells and drives the development of 95% of CML cases. BCR-ABL promotes leukemogenesis by activating downstream signaling proteins that increase cell survival and proliferation (4) . These pathways include, but are not limited to, the RAF/mitogenactivated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase/AKT (PI3K/AKT), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling cascades (5) .
The first-line treatment for CML is imatinib mesylate (IM), which binds to the ABL kinase domain and inhibits phosphorylation of substrates (6) . Although IM markedly improves patient survival when used to treat early-stage disease, the drug is not curative. Resistance to IM can develop, especially in advanced-stage disease, leading to disease relapse and progression (7) . Resistance to IM can result from multiple mechanisms that can be broadly classified as either BCR-ABL-dependent or BCR-ABL-independent (8) . BCR-ABL-dependent resistance is most commonly due to the acquisition of point mutations in the ABL kinase domain that interfere with IM binding and subsequent kinase inhibition (9) (10) (11) . However, in 50% or more of IM-resistant CML patients, there is no mutation in BCR-ABL (12, 13) , and the basis of such BCR-ABLindependent IM resistance is not understood.
CML, like several other malignancies, is propagated by a small population of stem cells, elimination of which is likely required to achieve long-term remission and cure (14, 15 ). An important limitation of IM treatment is that although IM inhibits BCR-ABL activity in CML stem cells, these cells do not depend on BCR-ABL activity for survival and are thus not eliminated (16, 17) . These findings imply that CML stem cells use survival signals other than BCR-ABL to maintain viability in the presence of IM. Understanding the mechanism by which CML stem cells are intrinsically resistant to IM is essential for devising strategies to eradicate residual leukemia. To gain insight into how IM resistance can occur in the absence of BCR-ABL mutations, we performed an RNA interference (RNAi) screen to identify genes that regulate IM responsiveness. Our results reveal a survival pathway that promotes BCR-ABL-independent IM resistance and also contributes to the IM resistance of CML stem cells.
RESULTS
A large-scale short hairpin RNA screen identifies IM-sensitizing genes To identify IM-sensitizing genes (IMSGs), IM-sensitive human CML K562 cells (18) were stably transduced with pools of a genome-wide human short hairpin RNA (shRNA) library (19) followed by IM treatment (Fig. 1A) . Surviving cells from all pools were combined, and shRNAs corresponding to 89 genes were identified by sequence analysis. Validation experiments with individual shRNAs corresponding to those isolated from the primary screen, as well as second, unrelated shRNAs targeting the same genes, confirmed that knockdown (KD) of 25 genes conferred more than twofold increased K562 cell survival in the presence of IM relative to a control nonsilencing (NS) shRNA ( To confirm that our results are generalizable, we analyzed the validated candidates in KYO-1 cells, another IM-sensitive human CML cell line (20) . Figure 1C shows that 21 of the 25 shRNA candidates validated in KYO-1 cells. Finally, we tested whether KD of the validated candidates would also confer IM resistance in BCR-ABL + mouse primary bone marrow cells. Toward this end, we induced CML-like disease in C57BL/6 mice with a BCR-ABLexpressing retrovirus (21, 22) . Primary bone marrow cells were harvested, infected with a mouse candidate IMSG shRNA, and tested for their ability to form colonies in methylcellulose containing IM. We found that KD of 19 candidate IMSGs ( fig. S3A ) rendered BCR-ABL + primary bone marrow cells IM-resistant (Fig. 1D) . Equivalent results were obtained with a second, unrelated shRNA for each IMSG ( fig. S3 , B and C).
To quantify IM resistance, we determined the half maximal inhibitory concentration (IC 50 
Pearson's R = 0.6731 P < 0.05 * * * * * * * * * * * * * * * * * * 1 KD K562 cells. KD of 11 IMSGs increased the IC 50 IM greater than fivefold ( Fig. 1E and fig. S4 ), and we therefore focused on these IMSGs in our subsequent experiments. Notably, the IC 50 IM s of these 11 IMSG KD K562 cell lines are similar to those of IM-resistant cell lines derived from CML patients (23) . These 11 IMSGs are involved in diverse biological processes including transcriptional regulation, signal transduction, protein metabolism, and DNA/RNA metabolism (table S1 ).
Next, we tested whether KD of IMSGs would cause resistance to the second-generation tyrosine kinase inhibitor dasatinib (24) . As a control, we analyzed in parallel K562R cells, which are resistant to IM but sensitive to dasatinib because of overexpression of the Src family kinase (SFK) LYN (25) . All of the IMSG shRNAs that conferred IM resistance also caused resistance to dasatinib (Fig. 1F) .
KD of IMSGs in BCR-ABL
+ cells results in sustained RAF/MEK/ERK signaling after IM treatment We next performed a series of experiments to identify the regulatory pathway(s) through which IMSGs promote IM sensitivity. IMSG KD K562 cell lines were cultured in the presence or absence of IM followed by immunoblotting for characteristic markers of relevant cell signaling pathways. The results in Fig. 2 indicate that KD of IMSGs had no effect on total BCR-ABL. Moreover, in all IMSG KD K562 cell lines, IM inhibited BCR-ABL protein kinase activity, as evidenced by decreased BCR-ABL autophosphorylation and decreased phosphorylation of the BCR-ABL substrate CRKL (26) . We also monitored the effect of IMSG KD on SFK activity, whose elevation, as mentioned above, is responsible for IM resistance in K562R cells. None of the IMSG KD K562 cell lines had elevated SFK activity or expression, consistent with their resistance to dasatinib.
We next analyzed the effect of IMSG KD on known downstream signaling pathways of BCR-ABL. All IMSG KD K562 cell lines had normal amounts of phosphorylated STAT5 and AKT, indicating that JAK/STAT and PI3K/AKT signaling pathways were not affected by IMSG KD. In contrast, most of the IMSG KD K562 cell lines had increased RAF/MEK/ERK kinase pathway activity, as evidenced by elevated phosphorylation of ERK1/2. As expected, after IM treatment of control K562 cells, there was a substantial decrease in phosphorylated ERK1/2. However, all of the IMSG KD K562 cell lines had, to varying extents, sustained phosphorylation of ERK1/2 after IM treatment. Thus, in IMSG KD K562 cell lines, there is an alternative pathway that activates RAF/MEK/ERK signaling after inhibition of BCR-ABL.
Previous studies have reported that the protein kinase C (PKC) pathway can stimulate RAF/MEK/ERK signaling (27) (28) (29) . We therefore analyzed PKC pathway activity in IMSG KD K562 cells by monitoring phosphorylation of a universal PKC substrate, MARCKS (30) . Phosphorylation of MARCKS was elevated in all IMSG KD K562 cell lines, indicating increased PKC activity.
PRKCH is up-regulated in BCR-ABL-independent IM-resistant CML cell lines and patient samples Next, we sought to identify the PKC family member(s) responsible for the increased PKC activity. The qRT-PCR results in Fig. 3A show that PRKCH, which encodes PKCh, was up-regulated in nearly all IMSG KD K562 cell lines. Similar results were obtained with a second shRNA targeting each IMSG ( fig. S5A ). Immunoblot analysis confirmed that PKCh protein levels were also increased in the IMSG KD K562 cell lines ( fig. S5B) .
As a first step toward understanding the basis by which IMSGs regulate PRKCH expression, we further analyzed one of the IMSGs, ELF5, a known transcriptional repressor (31, 32) . We used a chromatin immunoprecipitation assay and found that ELF5 was directly bound at the transcription start site of PRKCH ( fig. S6A) , consistent with the results of a study analyzing ELF5 occupancy genome-wide (33) . Moreover, we found that expression of a PRKCH promoter-luciferase reporter construct was increased by ELF5 KD and, conversely, decreased by ectopic expression of ELF5 ( fig. S6 , B and C). Thus, ELF5 is a direct transcriptional repressor of PRKCH, explaining why decreased ELF5 levels result in increased PRKCH expression.
To verify that increased PKCh expression is responsible for the IM resistance, we derived K562 cell lines that overexpressed PRKCH (K562/PRKCH cells) to varying degrees. In several K562/PRKCH cell lines, PKCh levels were comparable to those found in IMSG KD K562 cells ( fig. S7A ). The elevated PRKCH expression resulted in a 10-to 20-fold increase in IM resistance (Fig. 3B) . Conversely, KD of PRKCH abrogated the IM resistance of representative IMSG KD K562 cell lines ( fig. S7B ).
To determine the clinical relevance of these results, we analyzed PRKCH mRNA levels in IM-resistant CML patient samples harboring wild-type BCR-ABL. As a control, we also analyzed PRKCH mRNA levels in IM-resistant CML patient samples that contained a known IM resistance mutation in BCR-ABL (table S2) . The results in Fig. 3C show that PRKCH mRNA levels were significantly (P < 0.01) higher in IM-resistant CML patient samples containing wild-type BCR-ABL compared to those with mutant BCR-ABL. In addition, we found that the average expression of three IMSGs (CLEC5A, ELF5, and WNT7B) was significantly (P < 0.01, <0.05, and <0.05, respectively) lower in IM-resistant CML patient samples containing wild-type BCR-ABL compared to those with mutant BCR-ABL (Fig. 3D) . Moreover, in all 11 IM-resistant CML patient samples containing wild-type BCR-ABL, at least one IMSG was down-regulated
IM: more than twofold, and in 9 of 11 samples, at least one IMSG was down-regulated more than fivefold relative to the average expression in IM-resistant mutant BCR-ABL samples (table S3) . Finally, the results in Fig. 3E show that KD of PRKCH increased IM sensitivity of leukemic cells from BCR-ABLindependent IM-resistant CML patients.
PKCh increases RAF/MEK/ERK signaling through phosphorylation and activation of CRAF We next sought to understand in greater detail how PKCh increased RAF/MEK/ERK signaling. Figure 3F shows that even a relatively modest KD of PRKCH in IMsensitive K562 cells decreased both phosphorylated MEK and ERK1/2 (see also fig. S8A ) and increased IM sensitivity (fig. S7B). Conversely, K562/PRKCH cells had increased levels of both phosphorylated MEK and ERK1/2 ( Fig. 3F ). Most importantly, K562/PRKCH cells maintained high levels of phosphorylated MEK and ERK1/2 after IM treatment (Fig. 3F) .
The finding that PKCh affected both phosphorylated MEK and ERK1/2 indicated that PKCh functioned upstream of MEK by, for example, stimulating RAF activity. There are three known RAF kinases: ARAF, BRAF, and CRAF (34) . We found that in K562/PRKCH cells, KD of CRAF, but not ARAF or BRAF, decreased phosphorylated ERK1/2 ( Fig. 3G and fig. S8B ). Most importantly, in IM-treated K562/ PRKCH cells, KD of CRAF, but not ARAF or BRAF, resulted in loss of sustained phosphorylation of ERK1/2.
To determine whether CRAF was a direct substrate of PKCh, we derived a GST fusion protein containing a CRAF peptide bearing a potential PKC phosphorylation site at S 497 / S 499 (35, 36) . The in vitro kinase assay in Fig. 3H shows that wild-type PKCh, but not a kinase-dead mutant (K384R) (37), could phosphorylate the CRAF S 497 /S 499 site. Our results are consistent with several previous findings including phosphorylation of CRAF by PKC isoforms (35, 36, (38) (39) (40) and reduced activity of a CRAF S497A/S499A mutant (36, 38) .
IM and a MEK inhibitor synergistically kill BCR-ABL-independent IM-resistant CML cells
The results presented above show that BCR-ABL-independent IM resistance can 
Relative ELF5 expression
Relative WNT7B expression result from increased PRKCH expression, leading to sustained RAF/ MEK/ERK signaling after IM treatment. An implication of this conclusion is that simultaneous inhibition of BCR-ABL and RAF/MEK/ERK signaling might efficiently kill BCR-ABL-independent IM-resistant CML cells. To investigate this possibility, we analyzed the effect of combining IM treatment with the U.S. Food and Drug Administration (FDA)-approved MEK inhibitor trametinib (also called GSK1120212). We found that treatment with both IM and trametinib had a substantially greater effect than either drug alone in killing K562/PRKCH cells (Fig. 4A) , representative IMSG KD K562 cell lines (Fig. 4B) , and BCR-ABL + mouse primary bone marrow cells overexpressing Prkch (Fig. 4C) . In most instances, the effect of combined drug treatment was synergistic (table  S4) . The modest effect of trametinib alone on K562 cell lines likely reflects stimulation of RAF/MEK/ERK signaling by BCR-ABL. Finally, + mouse primary bone marrow cells ectopically expressing Prkch (E) or knocked down for an IMSG (F), and treated at day 7 with either IM, trametinib, or a combination of the two drugs as indicated (n = 4 or 5 mice per group). Data are represented as means ± SEM. The same NS control is used in the two graphs shown in (F), which were derived from a single experiment. (G and H) Kaplan-Meier survival curves of leukemic mice derived as described in (E) and (F). The indicated cohorts of mice (n = 5 for Prkch overexpression and n = 6 for IMSG KD) were treated with either vehicle, IM (100 mg/kg twice a day), trametinib (2 mg/kg once a day), or both IM and trametinib by oral gavage starting at day 7 (indicated by the arrow). The same NS control is used in the curves shown in (H), which were derived from a single experiment. *P ≤ 0.05, **P ≤ 0.01. Statistical tests and exact P values are provided in table S4. treatment with both IM and trametinib had a significantly (P < 0.01) greater effect than either drug alone in killing primary leukemic cells from BCR-ABL-independent IM-resistant CML patients (Fig. 4D and fig. S9A ). Moreover, these leukemic cells were killed more effectively by combined treatment with IM and trametinib than by IM and a JAK-STAT or PI3K inhibitor, and neither of these latter two drug combinations was significantly more effective than IM alone ( fig. S9B ).
IM and a MEK inhibitor prolong survival in mouse models of BCR-ABL-independent IM-resistant CML On the basis of the cell culture results, we analyzed the ability of this drug combination to prolong survival in mouse models of BCR-ABLindependent IM-resistant CML. Briefly, mouse primary bone marrow cells were transduced with a retrovirus coexpressing BCR-ABL and either Prkch (fig. S10A ) or an shRNA targeting one of two representative IMSGs, Clec5a or Elf5 (fig. S10 , B to D), followed by transplantation into lethally irradiated syngeneic mice. We found that combined treatment with IM and trametinib was substantially more effective than either drug alone at suppressing leukemic progression, as evidenced by a reduced WBC count (Fig. 4 , E and F) and prolonged survival (Fig. 4 , G and H). In addition to prolonged survival, the general appearance and behavior of mice treated with IM and trametinib were normal, suggesting minimal drug toxicity.
PRKCH modulates proliferation of BCR-ABL + cells, disease progression, and IM sensitivity The finding that KD of PRKCH in K562 cells reduced phosphorylated ERK1/2 (Fig. 3F) raised the possibility that PRKCH might modulate the proliferation and survival of BCR-ABL + cells and thus affect disease progression. To investigate this possibility, we transduced mouse primary bone marrow cells with a retrovirus coexpressing BCR-ABL and a Prkch shRNA (Fig. 5A) . Prkch KD decreased phosphorylated ERK1/2, similar to the results in K562 cells. Figure 5B shows that KD of Prkch ( fig. S11A ) reduced the ability of untreated BCR-ABL + mouse primary bone marrow cells to form colonies in methylcellulose (see also fig. S11B ). Moreover, the colony formation assay in Fig. 5C shows that KD of Prkch markedly increased the IM sensitivity of BCR-ABL + mouse primary bone marrow cells.
We next transplanted the Prkch KD bone marrow cells into syngeneic mice to induce CML-like disease and analyzed the effect of Prkch KD on leukemic progression. We found that in untreated mice, Prkch KD resulted in a lower WBC count (Fig. 5D ), reduced spleen size (Fig. 5E ), decreased infiltration of the lung and spleen by leukemic cells (Fig. 5F ), and an increase in survival (Fig. 5G) . Thus, in the absence of IM treatment, PRKCH promotes disease progression, although this effect may be relatively minor. KD of Prkch markedly increased survival of IM-treated mice with CML-like disease (Fig. 5G) .
IM-resistant murine and human CML stem cells contain high levels of PRKCH
We considered the possibility that PRKCH might contribute to the intrinsic resistance of CML stem cells to IM. To investigate this idea, we induced CML-like disease in mice and isolated BCR-ABL + murine stem cells (Lin (16, 45, 46 ) from newly diagnosed CML patients. The qRT-PCR results in Fig. 6B show that IM-resistant human CML stem cells [(15, 16, 47-49) and see below] had substantially higher expression of PRKCH compared to human CML progenitor cells, which are IMsensitive (16, 45) . Analysis of a published expression profiling study comparing highly enriched human CML stem and progenitor cell populations (50) revealed similar differences in PRKCH expression (Fig. 6C) . Microarray analysis indicates that PRKCH expression is much higher in hematopoietic stem cells than in mature myeloid cells (51, 52) , suggesting that high PRKCH expression may be a marker of stemness.
High Prkch expression contributes to the IM resistance of CML stem cells We performed several experiments to determine whether the high Prkch expression in murine CML stem cells contributes to their IM resistance. We first assessed the contribution of Prkch, and, as a comparison, BCR-ABL, to RAF/MEK/ERK signaling in murine CML stem cells. Prkch KD bone marrow cells were isolated from leukemic mice, permeabilized and incubated with an antibody against phosphorylated ERK1/2 or, as a negative control, immunoglobulin G (IgG) isotype antibody, and then analyzed by FACS to determine the phosphorylated ERK1/2 levels in CML progenitor and stem cells. Figure 7A shows that KD of Prkch reduced phosphorylated ERK1/2 in both CML progenitor and stem cells (see also fig. S13A ).
To evaluate the role of BCR-ABL, bone marrow cells were isolated from leukemic mice and treated with either IM or trametinib, and phosphorylated ERK1/2 was monitored as described above. Figure 7B shows, as expected, that trametinib reduced phosphorylated ERK1/2 in both CML progenitor and stem cells (see also fig. S13B ). In contrast, IM reduced phosphorylated ERK1/2 in IM-sensitive CML progenitor cells, but not in IM-resistant CML stem cells. Collectively, these results indicate that in CML stem cells, PKCh has a more prominent role than BCR-ABL in promoting RAF/MEK/ERK signaling.
We next performed a series of experiments to determine whether Prkch affects survival of CML stem cells after IM treatment. In the first experiment, mouse primary bone marrow cells were transduced with a retrovirus coexpressing BCR-ABL and either Prkch or a control NS shRNA, followed by transplantation into lethally irradiated syngeneic mice. BCR-ABL + murine stem cells (Lin
were isolated from the mice, and IM sensitivity was determined in a colony formation assay. The results in Fig. 7C show that Prkch KD markedly increased the IM sensitivity of CML stem cells. In the second experiment, mice with CMLlike disease were treated with either vehicle or IM in parallel for 2 weeks, and then sacrificed at the same time followed by quantification of CML stem cells by FACS analysis. Figure 7D shows, as expected, that IM treatment had little effect on the number of CML stem cells expressing a control NS shRNA, confirming that murine CML stem cells are IMresistant. In contrast, IM treatment markedly reduced the number of Prkch KD CML stem cells. Annexin V staining revealed that IM treatment induced a higher amount of apoptosis in Prkch KD compared to control CML stem cells (fig. S14, A and B) . Finally, combined treatment with IM and trametinib synergistically killed murine CML stem cells (Fig. 7E) , which was due, at least in part, to the induction of apoptosis ( fig. S14, C and D) . By contrast, treatment with IM and trametinib had negligible effect on normal murine hematopoietic stem cells (fig. S15A) .
KD of PRKCH also increased the IM sensitivity of IM-resistant human CML stem cells (Fig. 7F) . Moreover, treatment with both IM and trametinib had a substantially greater effect than either drug alone in killing human CML stem cells (Fig. 7G) , and a negligible effect on normal human hematopoietic CD34 + cells and hematopoietic stem cells (CD34 fig. S15B ). Collectively, these results indicate that PRKCH is expressed at relatively high levels in both mouse and human CML stem cells, and this contributes to their IM resistance.
DISCUSSION
Here, we have identified a molecular pathway whose increased activity promotes BCR-ABL-independent IM resistance and also contributes to the IM resistance of CML stem cells. Our major conclusions are summarized in the schematic model in Fig. 8 and discussed below. In typical IM-sensitive CML cells, BCR-ABL is the major contributor to RAF/MEK/ ERK signaling. Thus, treatment with IM substantially reduces RAF/MEK/ ERK signaling, leading to inhibition of proliferation and induction of apoptosis. In BCR-ABL-independent IM-resistant CML cells, elevation of PKCh, because of decreased expression of one or more IMSGs, results in phosphorylation and activation of CRAF, thereby augmenting RAF/MEK/ERK signaling. After treatment with IM, RAF/MEK/ ERK signaling is sustained, resulting in drug resistance.
A previous study analyzing IM resistance resulting from mutations in BCR-ABL found that IM treatment "paradoxically" increased RAF/ MEK/ERK signaling through a RAS-directed pathway (53) . Although the IM resistance mechanism we describe, like that in (53), involves increased RAF/MEK/ERK signaling, there are several important differences. For example, in our experiments, the increased RAF/MEK/ERK signaling is not dependent on RAS but rather initiated by PKCh, is constitutive and not induced by IM, and, as discussed below, is also relevant to the intrinsic IM resistance of CML stem cells. In addition, several reports have described experimentally derived BCR-ABL-independent IM-resistant CML cell lines in which RAF/MEK/ERK signaling is increased by a mechanism that was not determined (54) (55) (56) , or have provided other evidence that RAF/MEK/ERK signaling can contribute to IM resistance (57) (58) (59) (60) .
The mechanistic basis by which IMSGs regulate PRKCH expression is largely unknown. We showed that one of the IMSGs, ELF5, is directly bound at the transcription start site of PRKCH and can decrease PRKCH expression. Thus, ELF5 is a direct transcriptional repressor of PRKCH, explaining why decreased ELF5 levels result in increased PRKCH expression. Whether other IMSGs function directly or indirectly to regulate PRKCH expression remained to be determined. 
Human CML samples Human − and CD34 + CD38 + cells, mined from a previous expression profiling study (50) . Matched samples from the same patient are indicated by dots of the same color. Error bars indicate median with interquartile range. *P ≤ 0.05, **P ≤ 0.01. Statistical tests and exact P values are provided in table S4.
It is likely that our RNAi screen, like other large-scale RNAi screens (61), was not saturating, and thus, there are probably other IMSGs and regulators of PRKCH expression that remain to be identified. Our results suggest that a variety of diverse perturbations can increase PRKCH expression. A previous expression profiling study revealed that the level of PRKCH in CML cells increased after 1 week of IM treatment (62) , perhaps due to selection of and enrichment for cells with high PRKCH expression. This finding may also be explained by induction of PRKCH expression by IM treatment, although we found in IMSG KD K562 cell lines and CML stem cells that PRKCH is highly expressed in the absence of IM. In addition to its role in IM resistance, we found that elevated Prkch expression also accelerates disease progression in a mouse model of CML. Consistent with this idea, in a previous expression profiling study, PRKCH levels were found to increase during disease progression in CML patients. In the same study, the expression of seven of nine IMSGs analyzed decreased during disease progression (63) .
The IM resistance mechanism we describe is therapeutically targetable, which we demonstrate by showing that combined treatment with IM and the FDAapproved MEK inhibitor trametinib synergistically kills BCR-ABL + IMSG KD cells and prolongs survival in several mouse models of BCR-ABL-independent IMresistant CML. However, analysis of patientderived CML cell lines suggests that there may be variable responsiveness to MEK inhibition (64) . Our results are also relevant to another current challenge of CML treatment: the intrinsic resistance of CML stem cells to IM. We found that both human and murine CML stem cells contain high levels of PRKCH and provide evidence that this is responsible, at least in part, for their IM resistance. We further showed that the high PRKCH levels in CML stem cells promote RAF/MEK/ERK signaling, which helps explain why CML stem cells are not dependent on BCR-ABL for survival (16, 17) . Collectively, these results provide a rationale for our finding that CML stem cells, but not normal hematopoietic stem cells, are efficiently killed by combined treatment with IM and trametinib, and suggest a therapeutic strategy for their eradication.
MATERIALS AND METHODS

Study design
The overall study objective was to identify mechanisms underlying BCR-ABL-independent IM resistance in CML and CML stem cells. The study used cultured human CML cell lines, BCR-ABL + mouse primary bone marrow cells, mouse models of BCR-ABL-independent IM-resistant CML, and bone marrow or blood samples from CML patients. Institutional Review Board (IRB) approval for the acquisition of CML patient samples was obtained from the Department of Pathology at the University of Massachusetts Medical School (UMMS) (H00004484), the Druker lab at Oregon Health and Science University (OHSU) Knight Cancer Institute (4422), and the Hematology Bank at Winship Cancer Institute of Emory University (IRB00024964). All animal protocols were approved by the Institution Animal Care and Use Committee at UMMS (A-2300). The study consisted of a series of controlled laboratory experiments and measured multiple parameters including gene expression, cell viability, apoptosis, cell signaling pathway activity, and leukemic progression as described below. For animal experiments, mice were randomly allocated to each group for drug treatment after bone marrow transplantation, and were subsequently analyzed in a nonblinded fashion. Animal sample sizes were selected on the basis of precedent established from previous publications and an understanding that at least n = 5 is generally required to achieve statistical significance. Human CML samples were selected on the basis of sample availability and a requirement to achieve statistical significance. For mouse experiments involving shRNAs, the most efficacious shRNA of multiple shRNAs tested and validated in cell culture was used, a criterion that was established prospectively. All quantitative data were collected from experiments performed in, at least, triplicate. Original data for mouse and human studies are provided in 
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